Novartis' Kisqali shows 5-year survival in pivotal breast cancer study

 

• Novartis (NVS +0.5%) has announced updated median overall survival results for Kisqali (ribociclib), from Phase 3 MONALEESA-7 trial evaluating Kisqali plus endocrine therapy as initial treatment compared to endocrine therapy alone, in HR+/HER2- metastatic breast cancer.
• According to data presented at the San Antonio Breast Cancer Symposium, Kisqali plus endocrine therapy helped pre- and perimenopausal women with HR+/HER2- disease live a median 58.7 months, compared with 48 months for endocrine therapy alone, translating to a 24% reduction in the risk of death for the Kisqali regimen.
• Similar median survival benefit of 58.7 months was observed with Kisqali plus an aromatase inhibitor subgroup vs. 47.7 months in the placebo plus aromatase inhibitor subgroup.
• Kisqali regimen also extended the time period before patients need follow-up chemotherapy. Patients on Kisqali combo lived a median 50.9 months before their first post-treatment chemo, while the time was 36.8 months for endocrine therapy alone.
• The company is also testing Kisqali in combination with the endocrine therapy letrozole in another Phase 3 trial, Monaleesa-2, in previously untreated patients; overall survival data is expected in 2H of 2021.
• https://seekingalpha.com/news/3643060-novartis-kisqali-shows-5-year-survival-in-pivotal-breast-cancer-study